Evotec SE’s Seattle-based subsidiary Just – Evotec Biologics, Inc. has entered a collaboration with OncoResponse, Inc., a biotech company developing human antibodies for multiple high value targets associated with immunosuppressive myeloid biology. OncoResponse’s lead product candidate, OR2805, is a fully human antibody that reverses immunosuppression in the tumor microenvironment and promotes greater cancer killing, leading to higher response rates.

Just – Evotec Biologics will leverage its integrated technology platform, J.DESIGN, to provide OncoResponse with services to accelerate OR2805 into the clinic. The services include cell line development, process development, and Phase I/II cGMP clinical manufacturing of a selected drug candidate for use in human clinical trials.

Clifford Stocks, chief executive officer of OncoResponse, said, “We are thrilled to have Just – Evotec Biologics develop and manufacture our lead therapeutic antibody. Just – Evotec Biologics’ background, expertise and guidance combined with their track record and unique technology platform will play a critical role in the successful production of our molecule for clinical studies.”

Dr. James Thomas, executive vice president Global Head Biotherapeutics, president U.S. operations at Just – Evotec Biologics, said, “We are delighted to be working with the experienced and dynamic team at OncoResponse on the development and manufacturing of this exciting immunotherapy approach to cancer.”